GL
GLSI.US Greenwich Lifesciences Inc
- Market cap
- USD 219M
- P/E
- -
- P/B
- 71.91x
- ROE
- -616.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is GLSI.US undervalued?
Graham numberThe Graham number of Greenwich Lifesciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Greenwich Lifesciences Inc fundamental analysis
No fundamental analysis for Greenwich Lifesciences Inc yet.
Greenwich Lifesciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficac…
Full company profileGreenwich Lifesciences Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Greenwich Lifesciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.12K |
| Gross Profit | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -3.61K | -1.78K | - |
| Operating Income | -1.57M | -1.69M | -3.43M | -1.86M | -4.60M | -8.04M | -9.33M | -17.6M | -19.4M | -19.5M |
| EBITDA | -1.57M | -1.69M | -3.42M | -1.86M | -4.57M | -7.82M | -8.89M | -17.4M | -19.4M | -19.2M |
| Net Income | -1.57M | -1.69M | -3.43M | -1.86M | -4.57M | -7.83M | -8.89M | -17.4M | -19.4M | -19.2M |
| EPS | -0.13 | -0.14 | -0.29 | -0.15 | -0.35 | -0.61 | -0.69 | -1.34 | -1.43 | -1.31 |
| Balance Sheet | ||||||||||
| Total Assets | 27.1K | 109K | 26.7K | 28.7M | 27.2M | 13.5M | 6.99M | 4.09M | 6.18M | 8.88M |
| Total Liabilities | 8.56M | 10.2M | 1.38M | 1.05M | 385K | 263K | 294K | 3.19M | 5.82M | 5.76M |
| Shareholders' Equity | -8.53M | -10.1M | -1.35M | 27.6M | 26.8M | 13.2M | 6.70M | 909K | 353K | 3.12M |
| Cash & Short-term Investments | 54.00 | 85.1K | 6.84K | 28.7M | 27.2M | 13.5M | 6.99M | 4.09M | 6.18M | 8.88M |
| Total Debt | - | 420K | 635K | 275K | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -121K | -115K | -293K | -1.15M | -4.29M | -6.20M | -6.48M | -7.27M | -9.91M | -13.3M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00 | 0.00 | 3.00 | 3.00 | 6.00 |
| Free Cash Flow | -121K | -115K | -293K | -1.15M | -4.29M | -6.20M | -6.48M | -7.27M | -9.91M | -13.3M |
| Ratios | ||||||||||
| ROE | - | - | - | -6.7% | -17.0% | -59.2% | -132.7% | -1,916.5% | -5,480.5% | -616.4% |
| ROA | -5,805.3% | -1,556.6% | -12,842.8% | -6.5% | -16.8% | -58.1% | -127.1% | -425.4% | -313.3% | -216.4% |
| Net Profit Margin | - | - | - | - | - | - | - | - | - | -269,977.9% |
| Debt to Equity | - | - | - | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Greenwich Lifesciences Inc dividends
Greenwich Lifesciences Inc has not paid dividends in the last 9 fiscal years.
Who owns Greenwich Lifesciences Inc
- Insiders 47.91%
- Institutions 12.09%
- Public & others 40.00%
- Shares outstanding 14.7M
- Free float 7.65M
Top funds holding GLSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 199K | 1.36% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 196K | 1.33% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 75.0K | 0.51% | +0.91% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 73.1K | 0.50% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 45.5K | 0.31% | +17.87% | Sep 2026 |
| Vanguard US Momentum Factor ETF | 38.2K | 0.26% | +11.51% | Sep 2026 |
| Fidelity Extended Market Index | 33.3K | 0.23% | -0.37% | Sep 2026 |
| iShares Micro-Cap ETF | 23.6K | 0.16% | 0.00% | Oct 2026 |
| Ancora/Thelen Small-Mid Cap I | 20.0K | 0.14% | 0.00% | Sep 2026 |
| Schwab Small Cap Index | 19.2K | 0.13% | +18.16% | Sep 2026 |
| Stt Strt SPDR® Russell2000 US SmCapETF | 17.4K | 0.12% | -6.56% | Sep 2026 |
| Bridge Builder Small Cap Fund | 17.0K | 0.12% | 0.00% | Oct 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 14.7K | 0.10% | +25.50% | Sep 2026 |
| Fidelity Total Market Index | 12.3K | 0.08% | -0.06% | Sep 2026 |
| MFS Blended Research Small Cap Eq R6 | 11.4K | 0.08% | -0.65% | Sep 2026 |
| Fidelity Series Total Market Index | 9.63K | 0.07% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 8.96K | 0.06% | 0.00% | Aug 2026 |
| Vanguard Russell 2000 Growth ETF | 8.59K | 0.06% | +14.59% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 8.12K | 0.06% | 0.00% | Aug 2026 |
Top institutions holding GLSI.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 486K | 3.31% | +11.98% | Jun 2026 |
| Vanguard Capital Management, LLC | 278K | 1.90% | -6.73% | Jun 2026 |
| Geode Capital Management, LLC | 168K | 1.15% | +8.18% | Jun 2026 |
| State Street Corp | 143K | 0.97% | +6.88% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 80.9K | 0.55% | +37.26% | Jun 2026 |
| Northern Trust Corp | 80.2K | 0.55% | +6.79% | Jun 2026 |
| Bank of New York Mellon Corp | 47.9K | 0.33% | +2.96% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 46.0K | 0.31% | +2.35% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 43.4K | 0.30% | +45.66% | Jun 2026 |
| The Goldman Sachs Group Inc | 39.3K | 0.27% | -0.49% | Jun 2026 |
| Jane Street Group LLC | 27.7K | 0.19% | 0.00% | Jun 2026 |
| UBS Group AG | 23.4K | 0.16% | +10.86% | Jun 2026 |
| State Of Wisconsin Investment Board | 22.6K | 0.15% | +11.31% | Jun 2026 |
| GSA Capital Partners LLP | 19.5K | 0.13% | 0.00% | Jun 2026 |
| Massachusetts Financial Services Company | 17.9K | 0.12% | 0.00% | Jun 2026 |
| STRS OHIO | 17.8K | 0.12% | +29.93% | Jun 2026 |
| Charles Schwab Investment Management Inc | 17.1K | 0.12% | +2.98% | Jun 2026 |
| Vanguard Global Advisers, LLC | 11.9K | 0.08% | +14.86% | Jun 2026 |
| Ancora Advisors LLC | 10.7K | 0.07% | -71.36% | Jun 2026 |
| Stifel Financial Corp | 10.0K | 0.07% | 0.00% | Jun 2026 |
Greenwich Lifesciences Inc company profile
- Company name
- Greenwich Lifesciences Inc
- Ticker
- GLSI.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Fiscal year end
- December
- Address
- Building 14, Stafford, TX, United States, 77477
- Phone
- 832-819-3232
- Website
- greenwichlifesciences.com
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Greenwich Lifesciences Inc management
5- Mr. Snehal S. PatelCEO, CFO & Director · born 1964
- Mr. Eric RotheFounder & Independent Director · born 1975
- Dr. Frank Joseph Daugherty M.D.Chief Medical Officer & Director · born 1950
- Dr. Jaye L. Thompson Ph.D.Vice President Clinical & Regulatory Affairs · born 1966
- Dr. Christine T. Fischette Ph.D.VP of Business Development · born 1951